Biogen Inc. (BIIB)
Largest Insider Buys in Sector
BIIB Stock Price History Chart
BIIB Stock Performance
About Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Activity of Biogen Inc.
Over the last 12 months, insiders at Biogen Inc. have bought $101,256 and sold $524,267 worth of Biogen Inc. stock.
On average, over the past 5 years, insiders at Biogen Inc. have bought $918,558 and sold $3.17M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Rowinsky Eric K (director) — $303,767.
The last purchase of 455 shares for transaction amount of $101,256 was made by Rowinsky Eric K (director) on 2024‑02‑15.
List of Insider Buy and Sell Transactions, Biogen Inc.
| 2024-04-02 | Sale | Singhal Priya | Head of Development | 93 <0.0001% | $213.09 | $19,817 | +5.91% | |
| 2024-02-22 | Sale | Singhal Priya | Head of Development | 262 0.0002% | $221.23 | $57,962 | -1.38% | |
| 2024-02-16 | Sale | Singhal Priya | Head of Development | 108 <0.0001% | $221.49 | $23,921 | +0.20% | |
| 2024-02-15 | Rowinsky Eric K | director | 455 0.0003% | $222.54 | $101,256 | -1.77% | ||
| 2024-02-12 | Sale | Singhal Priya | Head of Development | 419 0.0003% | $239.45 | $100,330 | -10.24% | |
| 2024-02-02 | Sale | Singhal Priya | Head of Development | 634 0.0004% | $245.93 | $155,920 | -9.43% | |
| 2023-12-11 | Sale | Singhal Priya | Head of Development | 110 <0.0001% | $248.00 | $27,280 | -8.59% | |
| 2023-09-05 | Sale | Singhal Priya | Head of Development | 431 0.0003% | $269.43 | $116,124 | -12.91% | |
| 2023-07-03 | Sale | Singhal Priya | Head of Development | 81 <0.0001% | $282.87 | $22,912 | -15.27% | |
| 2023-04-28 | Sale | Gregory Ginger | EVP, Human Resources | 2,681 0.0018% | $300.00 | $804,300 | -15.82% | |
| 2023-04-04 | Sale | Singhal Priya | Head of Development | 91 <0.0001% | $277.11 | $25,217 | -5.93% | |
| 2023-03-28 | Sale | Singhal Priya | Head of Development | 568 0.0004% | $270.06 | $153,394 | -3.55% | |
| 2022-11-14 | Sale | Gregory Ginger | EVP, Human Resources | 5,610 0.0039% | $300.11 | $1.68M | -7.17% | |
| 2022-10-27 | Sale | ALEXANDER SUSAN H | EVP Chief Legal Off & Corp Sec | 5,532 0.0039% | $280.70 | $1.55M | +0.81% | |
| 2021-06-07 | Sale | Sandrock Alfred | Head of Research & Development | 7,672 0.0057% | $440.00 | $3.38M | -39.39% | |
| 2021-06-07 | Sale | Guindo Chirfi | Head of Glob Prod Strat & Com | 3,087 0.0023% | $440.00 | $1.36M | -39.39% | |
| 2021-06-04 | Sale | Posner Brian S | director | 360 0.0002% | $274.17 | $98,701 | -15.86% | |
| 2021-02-09 | Mantas Jesus B | director | 898 0.0006% | $267.00 | $239,766 | +1.75% | ||
| 2020-11-30 | Vounatsos Michel | Chief Executive Officer | 6,200 0.0039% | $241.31 | $1.5M | +14.86% | ||
| 2020-11-04 | Sale | Sandrock Alfred | EVP, Research & Development | 3,000 0.0018% | $350.00 | $1.05M | -22.40% |
Insider Historical Profitability
| Rowinsky Eric K | director | 20629 0.0078% | $224.46 | 1 | 6 | |
| Singhal Priya | Head of Development | 4886 0.0028% | $224.46 | 0 | 10 | |
| DENNER ALEXANDER J | director | 643000 0.4438% | $224.46 | 12 | 4 | +0.39% |
| SHARP PHILIP A | director | 468033 0.323% | $224.46 | 0 | 6 | |
| HANNA NABIL | EVP Discovery Research | 450905 0.3112% | $224.46 | 0 | 4 | |
| MULLEN JAMES C | CEO & President | 131149 0.0905% | $224.46 | 0 | 54 | |
| PICKETT CECIL B | President, R & D | 116135 0.0801% | $224.46 | 0 | 4 | |
| ROHN WILLIAM R | Chief Operating Officer | 65462 0.0452% | $224.46 | 0 | 13 | |
| SCANGOS GEORGE A | Chief Executive Officer | 54779 0.0378% | $224.46 | 0 | 47 | |
| BELZER ALAN | director | 40250 0.0278% | $224.46 | 0 | 3 | |
| ALEXANDER SUSAN H | EVP Chief Legal Off & Corp Sec | 39396 0.0272% | $224.46 | 0 | 16 | |
| Vounatsos Michel | Chief Executive Officer | 34810 0.024% | $224.46 | 5 | 0 | +8.6% |
| Hamm Robert A | Chief Operating Officer | 27212 0.0188% | $224.46 | 0 | 14 | |
| HASLER HANS PETER | Chief Operating Officer | 26858 0.0185% | $224.46 | 0 | 11 | |
| Cox John | EVP Pharmaceutical Oper & Tech | 25567 0.0176% | $224.46 | 0 | 11 | |
| Hasnain Faheem | EVP, Oncology/Rheumatology SBU | 25454 0.0176% | $224.46 | 0 | 4 | |
| WIGGINS MARK C | EVP Corp. and Bus. Dev. | 22780 0.0157% | $224.46 | 0 | 32 | |
| MATSUI CONNIE | EVP, Corp. Strategy and Comm. | 22571 0.0156% | $224.46 | 0 | 9 | |
| KELLOGG PETER N | EVP, Finance and CFO | 18966 0.0131% | $224.46 | 0 | 3 | |
| DUNN JOHN MICHAEL | EVP, New Ventures | 18712 0.0129% | $224.46 | 0 | 16 | |
| YOUNG WILLIAM | director | 18509 0.0128% | $224.46 | 0 | 5 | |
| PANGIA ROBERT W | director | 18587 0.0128% | $224.46 | 0 | 20 | |
| Kowolenko Michael | SVP, Pharm Ops & Technology | 18124 0.0125% | $224.46 | 0 | 4 | |
| DORSA CAROLINE | director | 17093 0.0118% | $224.46 | 8 | 2 | +28.27% |
| SHERWIN STEPHEN A | director | 14353 0.0099% | $224.46 | 0 | 8 | |
| ADELMAN BURT A | EVP, Portfolio Strategy | 12769 0.0088% | $224.46 | 0 | 21 | |
| WILLIAMS DOUGLAS E | EVP Research & Development | 11817 0.0082% | $224.46 | 0 | 3 | |
| MacLean Michael F | SVP, Chief Accounting Officer | 11634 0.008% | $224.46 | 0 | 7 | |
| Clancy Paul J | Executive VP and CFO | 10813 0.0075% | $224.46 | 0 | 14 | |
| Sandrock Alfred | Head of Research & Development | 10169 0.007% | $224.46 | 0 | 25 | |
| SCHNEIER CRAIG ERIC | EVP, HR, Public Affairs & Comm | 10201 0.007% | $224.46 | 0 | 41 | |
| ROSS BRUCE | director | 9900 0.0068% | $224.46 | 0 | 12 | |
| Pawlicki Raymond | SVP, Chief Information Officer | 8710 0.006% | $224.46 | 0 | 5 | |
| Gregory Ginger | EVP, Human Resources | 8483 0.0059% | $224.46 | 0 | 2 | |
| LEAMING NANCY | director | 7660 0.0053% | $224.46 | 0 | 11 | |
| Posner Brian S | director | 7400 0.0051% | $224.46 | 0 | 14 | |
| Karaboutis Adriana | EVP, Tech, Bus. Sol & Corp Aff | 7360 0.0051% | $224.46 | 0 | 7 | |
| RODRIGUEZ EDWARD | VP and Controller | 7100 0.0049% | $224.46 | 0 | 2 | |
| PAPADOPOULOS STELIOS | director | 5000 0.0035% | $224.46 | 1 | 2 | <0.0001% |
| Ehlers Michael D | EVP, Research and Development | 4281 0.003% | $224.46 | 0 | 1 | |
| Holtzman Steven H | EVP Corporate Development | 4321 0.003% | $224.46 | 0 | 9 | |
| Gagnon Robert E. | Vice President, Finance | 3999 0.0028% | $224.46 | 0 | 15 | |
| GLASSBERG ALAN | director | 3550 0.0024% | $224.46 | 0 | 8 | |
| Kingsley Stuart A | EVP, Global Comm. Operations | 3511 0.0024% | $224.46 | 0 | 3 | |
| SCHENK LYNN | director | 3100 0.0021% | $224.46 | 0 | 11 | |
| Guindo Chirfi | Head of Glob Prod Strat & Com | 2919 0.002% | $224.46 | 0 | 1 | |
| Mantas Jesus B | director | 2943 0.002% | $224.46 | 1 | 0 | +1.75% |
| Koppel Adam | EVP, Strategy and Bus. Dev. | 2402 0.0017% | $224.46 | 0 | 2 | |
| Mulligan Richard | director | 2020 0.0014% | $224.46 | 0 | 3 | |
| KELLER THOMAS F | director | 1250 0.0009% | $224.46 | 0 | 9 | |
| Artavanis-Tsakonas Spyridon | SVP, Chief Scientific Officer | 352 0.0002% | $224.46 | 0 | 1 | |
| GOOD MARY L | director | 0 0% | $224.46 | 0 | 5 | |
| Gilman Michael | EVP - Research | 0 0% | $224.46 | 0 | 3 | |
| BUCKNUM THOMAS J | EVP and General Counsel | 0 0% | $224.46 | 0 | 4 | |
| DiPietro Kenneth | EVP Human Resources | 0 0% | $224.46 | 0 | 6 | |
| Granata Francesco | EVP Global Commercial Operatio | 0 0% | $224.46 | 0 | 1 | |
| RASTETTER WILLIAM H | Executive Chairman | 0 0% | $224.46 | 0 | 4 |
Institutional Investor Ownership
| The Vanguard Group | $3.57B | 11.38 | 16.57M | +15.01% | +$466.42M | 0.07 | |
| PRIMECAP Management Co | $3.5B | 11.14 | 16.22M | -0.27% | -$9.44M | 2.63 | |
| BlackRock | $3.05B | 9.72 | 14.14M | -0.71% | -$21.92M | 0.07 | |
| State Street | $1.45B | 4.63 | 6.75M | -2.86% | -$42.84M | 0.06 | |
| T Rowe Price Investment Management Inc | $1.11B | 3.55 | 5.17M | -3.5% | -$40.4M | 0.68 | |
| Wellington Management Company | $1.1B | 3.52 | 5.12M | -3.84% | -$44.04M | 0.19 | |
| JPMorgan Chase | $1.01B | 3.22 | 4.69M | -6.32% | -$68.27M | 0.09 | |
| Geode Capital Management | $733.41M | 2.34 | 3.41M | +3.03% | +$21.59M | 0.07 | |
| VanEck | $374.62M | 1.19 | 1.74M | +22.25% | +$68.17M | 0.57 | |
| Morgan Stanley | $366.87M | 1.17 | 1.7M | +7.83% | +$26.65M | 0.03 | |
| Invesco | $359.67M | 1.15 | 1.67M | -8.08% | -$31.62M | 0.08 | |
| T. Rowe Price | $342.77M | 1.09 | 1.59M | +5.39% | +$17.53M | 0.04 | |
| Beutel, Goodman & Company Ltd. | $337.63M | 1.08 | 1.57M | +57.29% | +$122.98M | 1.74 | |
| ClearBridge Investments | $336.74M | 1.07 | 1.56M | -7% | -$25.37M | 0.27 | |
| Legal & General | $334.41M | 1.07 | 1.55M | -1.08% | -$3.65M | 0.08 | |
| Northern Trust | $299.38M | 0.95 | 1.39M | -7.13% | -$22.98M | 0.05 | |
| BNY Mellon | $296.71M | 0.95 | 1.38M | -0.99% | -$2.95M | 0.06 | |
| Dimensional Fund Advisors | $284.84M | 0.91 | 1.32M | -7.28% | -$22.36M | 0.08 | |
| Deutsche Bank | $228.02M | 0.73 | 1.06M | -11.13% | -$28.56M | 0.1 | |
| Goldman Sachs | $214.41M | 0.68 | 994,365 | -9.26% | -$21.88M | 0.04 | |
| Amundi | $187.81M | 0.68 | 985,802 | -17.97% | -$41.13M | 0.08 | |
| Ubs Asset Management Americas Inc | $209.62M | 0.67 | 972,143 | -4.18% | -$9.15M | 0.08 | |
| OrbiMed | $194.26M | 0.62 | 900,900 | +8.86% | +$15.81M | 3.97 | |
| Renaissance Technologies | $190.77M | 0.61 | 884,704 | +16.62% | +$27.19M | 0.3 | |
| Charles Schwab | $185.18M | 0.59 | 858,805 | +1.16% | +$2.11M | 0.04 | |
| American Century Investments | $181.66M | 0.58 | 842,467 | -14.79% | -$31.53M | 0.11 | |
| Ameriprise Financial | $172.3M | 0.55 | 798,660 | +294.43% | +$128.62M | 0.05 | |
| RA Capital Management, L.P. | $159.72M | 0.51 | 740,727 | +39% | +$44.82M | 0.16 | |
| Fil Ltd | $151.46M | 0.48 | 702,412 | +6.99% | +$9.9M | 0.15 | |
| Sarissa Capital Management LP | $138.65M | 0.44 | 643,000 | 0% | +$0 | 24.26 | |
| Allianz Asset Management Gmbh | $133.74M | 0.43 | 620,244 | -13.7% | -$21.23M | 0.23 | |
| Fidelity Investments | $133.87M | 0.43 | 620,850 | -37.99% | -$82M | 0.01 | |
| Massachusetts Financial Services Co Ma | $123.98M | 0.4 | 574,975 | -0.88% | -$1.1M | 0.04 | |
| Barclays | $116.56M | 0.37 | 540,565 | +1.56% | +$1.79M | 0.05 | |
| UBS | $102.6M | 0.33 | 475,826 | +40.63% | +$29.64M | 0.03 | |
| Standard Life | $98.3M | 0.31 | 455,864 | +4.3% | +$4.05M | 0.19 | |
| Bank of America | $95.66M | 0.31 | 443,622 | +4% | +$3.68M | 0.01 | |
| Swiss National Bank | $93.56M | 0.3 | 433,900 | -4.2% | -$4.1M | 0.06 | |
| AXA | $87.94M | 0.28 | 407,838 | -9.52% | -$9.25M | 0.27 | |
| Royal Bank of Canada | $87.3M | 0.28 | 404,861 | +8.25% | +$6.65M | 0.02 | |
| CalPERS | $87.2M | 0.28 | 404,419 | +11.35% | +$8.89M | 0.06 | |
| Camber Capital Management Lp | $86.25M | 0.28 | 400,000 | New | +$86.25M | 3.04 | |
| HSBC | $85.98M | 0.27 | 398,842 | +22.49% | +$15.79M | 0.06 | |
| Franklin Templeton Investments | $83.14M | 0.27 | 385,583 | -22.63% | -$24.32M | 0.03 | |
| Sumitomo Mitsui Trust Holdings | $83.34M | 0.27 | 386,482 | +0.88% | +$728,829.40 | 0.06 | |
| Td Asset Management Inc | $79.19M | 0.25 | 367,236 | -5.83% | -$4.91M | 0.07 | |
| Parnassus Investments Ca | $77.79M | 0.25 | 360,742 | 0% | +$0 | 0.17 | |
| Nuveen | $74.85M | 0.24 | 347,116 | -22.37% | -$21.57M | 0.02 | |
| First Trust | $72.08M | 0.23 | 334,296 | -65.79% | -$138.65M | 0.07 | |
| Two Sigma | $70.39M | 0.22 | 326,425 | +504.21% | +$58.74M | 0.12 |